A comprehensive review of the seasonal influenza type B Yamagata lineage circulation (scientific content for lectures preparation)

• Svetlana V. Nikolaeva
• Sergey A. Novoselov

Abstract

Seasonal influenza is one of the most common infectious diseases with significant social and economic impact. Seasonal influenza vaccination is crucial and high-priority process. For vaccines for use in 2024/2025 season in northern hemisphere influenza season WHO recommended A/Victoria/4897/2022 (H1N1)pdm09, A/Thailand/8/2022 (H3N2), B/Austria/1359417/2021 (B/Victoria lineage) and B/Phuket/3073/2013 (B/Yamagata lineage) strains. There have been no confirmed naturally occurring B/Yamagata lineage virus detections after March 2020. Therefore the WHO influenza vaccine composition advisory committee discussed that the B/Yamagata lineage antigen should be excluded from influenza vaccines. Despite the fact, that no confirmed cases of B/Yamagata were detected by WHO in last couple of years, quadrivalent vaccines are still high efficient in decreasing morbidity, mortality and economic burden of seasonal influenza.

Keywords: influenza virus; B Yamagata lineage; B Victoria lineage; quadrivalent vaccine; QIV; trivalent vaccine; TIV; immunoprophylaxis

References

1. On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2022: State report. Moscow: Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka, 2023: 368 p. (in Russian)

2. Sel’kova E.P., Kalyuzhin O.V. ARVI and influenza: to help the practicing physician. Moscow: Meditsinskoe informatsionnoe agentstvo, 2015: 224 p. (in Russian)

3. Belongia E.A., Irving S.A., Waring S.C., Coleman L.A., Meece J.K., Vandermause M., et al. Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008–2009 (H1N1), and 2007–2008 (H3N2) infections. JAMA. 2010; 304: 1091–8.

4. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al.; Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2010; 59: 1–62.

5. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza – United States, 1976–2007. MMWR Morb Mortal Wkly Rep. 2010; 59: 1057–62.

6. Ramos I., Fernandez-Sesma A. Innate immunity to H5N1 influenza viruses in humans. Viruses. 2012; 4 (12): 3363–88. DOI: https://doi.org/10.3390/v4123363

7. Teijaro J.R., Walsh K.B., Long J.P., Tordoff K.P., Stark G.V., Eisfeld A.J., et al. Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapy. Virology. 2014; 452–453: 152–7. DOI: https://doi.org/10.1016/j.virol.2014.01.003

8. Esposito S., Nauta J., Lapini G., Montomoli E., van de Witte S. Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: a global, multiseasonal, controlled, randomized phase III study. Vaccine. 2022; 40 (18): 2626–34. DOI: https://doi.org/10.1016/j.vaccine.2022.02.088 PMID: 35315323.

9. Webster R.G., Govorkova E.A. Continuing challenges in influenza. Ann N Y Acad Sci. 2014; 1323 (1): 115–39. DOI: https://doi.org/10.1111/nyas.12462

10. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12 (1): 36–44. DOI: https://doi.org/10.1016/S1473-3099(11)70295-X

11. World Health Organisation. Recommended composition of influenza virus vaccines for use in the 2024–2025 northern hemisphere influenza season [Electronic resource]. 2018. URL: https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations (date of access April 23, 2024).

12. Rota P.A., Wallis T.R., Harmon M.W., Rota J.S., Kendal A.P., Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990; 175 (1): 59–68.

13. Centers for Disease Control and Prevention (CDC). Update: influenza activity – worldwide, 1996. MMWR Morb Mortal Wkly Rep. 1996; 45 (38): 816–9.

14. Levandowski R.A., Regnery H.L., Staton E., Burgess B.G., Williams M.S., Groothuis J.R. Antibody responses to influenza B viruses in immunologically unprimed children. Pediatrics. 1991; 88: 1031–6.

15. Belshe R.B. The need for quadrivalent vaccine against seasonal influenza. Vaccine. 2010; 28: D45–53.

16. Reina J. Los linajes Victoria y Yamagata de los virus gripales B, desconocidos y poco valorados [The Victoria and Yamagata Lineages of Influenza B Viruses, unknown and undervalued]. Rev Esp Quimioter. 2022; 35 (3): 231–5. DOI: https://doi.org/10.37201/req/159.2021 PMID: 35180825; PMCID: PMC9134891. (in Spanish)

17. Paget J., Caini S., Del Riccio M., van Waarden W., Meijer A. Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines? Euro Surveill. 2022; 27 (39): 2200753. DOI: https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200753 PMID: 36177871; PMCID: PMC9524051.

18. Uskov A.A., Shipilov M.V., Tutel’yan A.V. Pharmacoeconomic analysis of using a quadrivalent influenza vaccine in the Russian Federation. Infektsionnye bolezni [Infectious Diseases]. 2020; 18 (1): 96–101. (in Russian)

19. McLean H.Q., Peterson S.H., King J.P., Meece J.K., Belongia E.A. School absenteeism among school-aged children with medically attended acute viral respiratory illness during three influenza seasons, 2012–2013 through 2014–2015. Influenza Other Respir Viruses. 2017; 11 (3): 220–9. DOI: https://doi.org/10.1111/irv.12440

20. Order of the Government of the Russian Federation of September 18, 2020 No. 2390-р [Electronic resource]. 2020. URL: http://publication.pravo.gov.ru/Document/View/0001202009280074 (date of access April 23, 2024).

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)